Blastomycosis Treatment Market Trends

  • Report ID: 3667
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Blastomycosis Treatment Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Population of Immunocompromised Patients – On account of the increasing immunodeficiencies, and malnutrition the market is expected to expand more in the upcoming years. Further, patients with weakened immune systems are more vulnerable to bacterial, fungal, viral, and parasitic illnesses. According to estimates, there are over 9 million immunocompromised individuals in the US, which is more than 3% of the total population.

  • Rising Geriatric Population – The elderly population is more prone to fungal infections owing to a weakened immune system is estimated to drive market growth. As of 2050, the number of individuals over 60 in the world is expected increase by over 2 billion.

  • Increasing Health Care Spending – According to the most recent expenditure data, U.S. health care spending increased by over 2% in 2021. It is predicted that this boom would continue over the forecast period.

  • Growing Prevalence of Malnutrition – It is expected that rising poverty is anticipated to drive the incidence of malnutrition which is further expected to propel the market growth. The World Health Organization (WHO) estimates that undernutrition accounts for over 45% of child mortality in low- and middle-income countries.

Challenges

  • Diagnoses of Blastomycosis can be Challenging - The increasing concern amongst individuals for the difficulty associated with the diagnosis is one of the major factors predicted to slow down the market growth. For instance, the position of radiographic findings in pulmonary blastomycosis might vary, which can result in an inaccurate diagnosis.

  • Growing Availability of Generic Medicines in the Market

  • Exorbitant Cost of Treatment


Base Year

2024

Forecast Year

2025-2037

CAGR

6.7%

Base Year Market Size (2024)

USD 202.46 million

Forecast Year Market Size (2037)

USD 470.41 million

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of blastomycosis treatment is evaluated at USD 224.75 million.

The blastomycosis treatment market size was over USD 202.46 million in 2024 and is poised to exceed USD 470.41 million by 2037, witnessing over 6.7% CAGR during the forecast period i.e., between 2025-2037. Growing population of immunocompromised patients and the rising geriatric population will boost the market growth.

Asia Pacific industry is predicted to dominate majority revenue share of 40% by 2037, attributed to rising malnutrition and unsanitary conditions in the region.

The major players in the market are Emcure Pharmaceuticals Limited, Viatris Inc., Hindustan Antibiotics Limited, Sun Pharmaceutical Industries Ltd., Novartis AG, Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos